Undisclosed IBD therapeutic / Novome Biotech - LARVOL DELTA

Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes (Yahoo Finance) - "Novome Biotechnologies, Inc...announced the close of a $43.5 million Series B financing. The financing was led by Tencent, and includes new investors University of Minnesota, Navian Investments, Colorcon Ventures and Touchdown Ventures. Existing investors DCVC Bio, 5AM Ventures, Alta Partners and Alexandria Venture Investments also participated in the financing....The proceeds will be used to advance both Novome’s clinical hyperoxaluria candidate, NOV-001, through an ongoing Phase 2a clinical trial and multiple Genetically Engineered Microbial Medicines (GEMMs) candidates for the potential treatment of inflammatory bowel disease (IBD)..."

Financing • Inflammatory Bowel Disease